ADC Therapeutics SA (ADCT) 2020年年度报告「NYSE」.pdf

1、ADC Therapeutics SA2020 Annual ReportAnnual Report1Table of ContentsLetter to Shareholders3Business Update5Financial Review76Corporate Governance98Report from the Auditor on the Consolidated IFRS Financial Statements124Consolidated IFRS Financial Statements for the Year Ended December 31,2020131Repo

2、rt from the Auditor on the Statutory Financial Statements of ADC Therapeutics SA180Statutory Financial Statements of ADC Therapeutics SA for the Year Ended December 31,2020185Report from the Auditor on the Compensation Report of ADC Therapeutics SA202Compensation Report of ADC Therapeutics SA for th

3、e Year Ended December 31,2020205Forward Looking Statements218Annual Report2DearShareholders,2020wasatransformationalyearforADCTherapeuticsaswemaderemarkableprogressacrossmanyaspectsofthebusinessandpositionedourselvesforcommercialsuccess.Highlightsincludethefirstregulatorysubmissionforourleadclinical

4、programloncastuximabtesirine(Lonca),thesuccessfulcompletionofourinitialpublicofferingandthestrategicgrowthofthecompanyworldwide.Iamveryproudofourachievements,especiallyconsideringthechallengespresentedbytheCOVID-19pandemic.Iwouldliketothankourcommittedemployeesandthededicatedphysiciansandpatientsinv

5、olvedinourclinicaltrialsfortheirtremendouseffortsandcontributions.IfitisapprovedbytheFDA,wewillbereadytolaunchourfirstproduct-Lonca.Webroughtonanaccomplishedseniorcommercialleaderwhoimmediatelysethersightsonthemosttalentedandexperiencedcommercialrepresentativesinhematology/oncology.ChiefCommercialOf

6、ficerJenniferHerronhasassembledaverystrongteamofexperiencedhematologytherapeuticspecialistswhoarewellconnectedtokeyhematologist/oncologistsandtheircolleagues.InthisCOVID-19environment,ourteamsaretrainedandpreparedtooptimizecustomerengagementwithahybridapproachandstrongdigitalsupportdependingonlocalg